TELA Bio

76 articles with TELA Bio

• TELA Bio Reports Strong Third Quarter 2021 Revenues Reflecting Continued Growth Driven by Increased Demand

  11/10/2021

  TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, reported third quarter 2021 financial results.

• TELA Bio Announces Publication of 12-Month Results from the BRAVO Study with Continued Positive Outcomes Through 24 months

  11/9/2021

  TELA Bio, Inc. today announced the publication of the 12-month analysis from the BRAVO Study in the Journal of Clinical Medicine.

• TELA Bio to Participate in Three Upcoming Conferences

  11/8/2021

  TELA Bio, Inc. today announced that the Company will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, 12th Annual Jefferies London Healthcare Conference

• TELA Bio and Next Science Enter into Exclusive Distribution Agreement in the Plastic Reconstructive Market for Advanced Anti-Biofilm Surgical Wash

  11/1/2021

  TELA Bio, Inc. today announced it has entered into a distribution agreement with Next Science granting TELA exclusive rights to sell and market Next Science's proprietary antimicrobial surgical wash with XBIO ® technology.

• TELA Bio to Announce Third Quarter 2021 Financial Results

  10/27/2021

  TELA Bio, Inc. ("TELA"), today announced that the company will report third quarter 2021 financial results on Wednesday, November 10, 2021.

• TELA Bio Appoints Roberto Cuca as Chief Operating Officer and Chief Financial Officer

  9/27/2021

  TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced the appointment of Roberto Cuca as the Company's new Chief Operating Officer and Chief Financial Officer.

• TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinforced Biologic Augmented Repair) Technique

  9/13/2021

  TELA Bio, Inc. today announced details of the clinical research presented last week at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting in Las Vegas, Nevada.

• TELA Bio's OviTex® Reinforced Tissue Matrix to be Featured in Three Presentations at SAGES 2021

  8/16/2021

  TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced three upcoming poster presentations on its OviTex Reinforced Tissue Matrix portfolio.

• TELA Bio to Participate in Canaccord Genuity’s 41st Annual Growth Conference

  8/3/2021

  TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the Company will participate in Canaccord Genuity’s 41st Annual Growth Conference.

• TELA Bio to Announce Second Quarter 2021 Financial Results

  7/28/2021

  TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report second quarter 2021 financial results on Wednesday, August 11, 2021.

• NHS Surgeon First in Europe to Implant TELA Bio's OviTex® LPR Reinforced Tissue MatrixMr. Paul Wilson, Consultant General Surgeon, successfully completes complex hernia repair with minimally invasive approach

  7/21/2021

  TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced today the first use of its OviTex LPR Reinforced Tissue Matrix in Europe.

• TELA Bio to Participate in Upcoming JMP Securities Life Sciences Conference

  6/14/2021

  TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the Company will participate in the JMP Securities Life Sciences Conference.

• TELA Bio Announces Changes to its Board of Directors - June 02, 2021

  6/2/2021

  TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that it has appointed John Nosenzo, the Chief Commercial Officer of Bioventus Inc., to its board of directors effective June 2, 2021.

• TELA Bio Names Marissa Conrad as Vice President of Clinical and Regulatory Affairs

  5/25/2021

  TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced the appointment of Marissa Conrad as the company's Vice President of Clinical and Regulatory Affairs effective May 24, 2021.

• TELA Bio to Participate in Upcoming Investor Conferences - May 21, 2021

  5/21/2021

  TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the Company plans to participate in two upcoming investor conferences.

• TELA Bio Initiates BRAVO II Study of OviTex® for the Robotic Repair of Ventral Hernias

  5/19/2021

  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today launched the company's second post-market study, BRAVO II, to evaluate the clinical performance of OviTex® Reinforced Tissue Matrices in the robotic repair of ventral hernias.

• TELA Bio Announces First Quarter 2021 Financial Results

  5/13/2021

  TELA Bio, Inc., a commercial stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, reported financial results for the first quarter ended March 31, 2021.

• TELA Bio to Announce First Quarter 2021 Financial Results

  4/29/2021

  TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report first quarter ended March 31, 2021, financial results on Thursday, May 13, 2021.

• TELA Bio Announces Fourth Quarter and Full Year 2020 Financial Results

  3/24/2021

  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial results for the fourth quarter and full year ended December 31, 2020.   Recent Highlights

• TELA Bio Announces 12-Month Analysis from BRAVO Study of OviTex® for Ventral Hernia Repair

  3/18/2021

  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the results of the 12-month analysis from the company's post-market BRAVO study evaluating the clinical performance of OviTex Reinforced Tissue Matrix for the treatment of ventral hernias.